First Line Trials NSCLC


Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

     ClinicalTrials.gov Identifier:              NCT04613596    
 
This study is currently recruiting participants.
 
Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.

Alberta
Cross Cancer Institute, Edmonton
Contact: Quincy Chu    780 432-8248     
 
British Columbia
BCCA - Cancer Centre for the Southern Interior, Kelowna
Contact: Sara Kristina Taylor    250 712-3996     

BCCA - Vancouver Cancer Centre, Vancouver
Contact: Daniel John Renouf    604 877-6000 ext 672357
     
Ontario
Kingston Health Sciences Centre, Kingston
Contact: Francisco Vera-Badillo    613 533-6430 ext 79893     

London Regional Cancer Program, London
Contact: Stephen Welch    519 685-8640     

Ottawa Hospital Research Institute, Ottawa
Contact: John Hilton    613 737-7700 ext 75086     

University Health Network, Toronto
Contact: Lillian Siu    416 946-2911
     
Quebec
The Jewish General Hospital, Montreal
Contact: Petr Kavan    514 398-1444
     
Saskatchewan
Allan Blair Cancer Centre, Regina
Contact: Kimberly Hagel    306 766-2691     

Saskatoon Cancer Centre, Saskatoon
Contact: Sunil K. Yadav    306 655-2710

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

     ClinicalTrials.gov Identifier:              NCT05948865    
 
This study is currently recruiting participants.
 

The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors.
 
The main questions it aims to answer are:
  • To assess the safety and tolerability of CPO301 at increasing doses and determine the dose to be used in the second part of the study (Part A)
  • To assess the safety and tolerability of CPO301 at the dose determined to be safe and tolerable in Part A in patients with Non-Small Cell Lung Cancer and potentially other tumor types (Part B)
  • To evaluate how quickly CPO301 is metabolized by the body (pharmacokinetics or PK)
  • To evaluate if antibodies to the study drug develop (immunogenicity)
  • To evaluate preliminary efficacy to the drug
  • To correlate preliminary efficacy with mutations in a biomarker called EGFR
 
Participants will:
  • Provide written informed consent
  • Undergo screening tests to ensure they are eligible for study treatment
  • Attend all required study visits and receive CPO301 by intravenous injection every 3 weeks until the study doctor determines study treatment should be stopped, based on how well a participant is doing on treatment
  • Be followed for progression every 3 months for up to 2 years
 
Alberta
Cross Cancer Institute, Edmonton
Principal Investigator: Quincy Chu, MD
 
Ontario
Juravinski Cancer Centre, Hamilton
Principal Investigator: Rosalyn Juergens, MD, PhD
 

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

      ClinicalTrials.gov Identifier:            NCT04931654    
 
This study is currently recruiting participants.
 
This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced solid tumors.

Alberta
Edmonton
 
Ontario
Toronto
 

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/​- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

      ClinicalTrials.gov Identifier:            NCT03847649    
 
This study is currently recruiting participants.
 
I238A: The purpose of this study is to find out what effects being treated with durvalumab has on cancer. The researchers doing this study also want to evaluate if prednisone (a type of steroid), when given together with durvalumab, can reduce any side effects. 
I238B: The purpose of this study is to allow patients previously enrolled on a completed CCTG trial to continue treatment with durvalumab (+/- tremelimumab)
 
Alberta
Edmonton
Cross Cancer Institute
Contact: Quincy Chu 780 432-8248
 
British Columbia
Kelowna
BCCA - Cancer Centre for the Southern Interior
Contact: Sara Kristina Taylor 250 712-3996
 
Vancouver
BCCA - Vancouver Cancer Centre
Contact: Christian Kollmannsberger 604 877-6000 ext 2734
 
New Brunswick
Saint John
Regional Health Authority B, Zone 2
Contact: Anthony J. Reiman 506 648-6884
 
Ontario
Hamilton
Juravinski Cancer Centre at Hamilton Health Sciences
Contact: Peter Ellis 905 387-9495
 
Kitchener
Grand River Regional Cancer Centre
Contact: Stacey Hubay 519 749-4370 ext 5262
 
Ottawa
Ottawa Hospital Research Institute
Contact: Scott Laurie 613 737-7700 ext 70173
 
Toronto
University Health Network
Contact: Penelope A. Bradbury 416 946-4501 ext 3544
 
Windsor
Windsor Regional Cancer Centre
Contact: Swati Kulkarni 519 253-5353
 
Quebec
Montreal
CHUM-Centre Hospitalier de l'Universite de Montreal
Contact: Normand Blais 514 890-8444
 
Quebec City
CHU de Quebec-Hopital l'Enfant-Jesus (HEJ)
Contact: Andre Blais 418 682-7511

Saskatchewan
Saskatoon
Saskatoon Cancer Centre
Contact: Nayyer Iqbal 306 655-2710

AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (MTAP)

      ClinicalTrials.gov Identifier:    

       NCT05094336    

 

This study is currently recruiting participants.
 

The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.
 
The primary objective of Part 3 of this study is to evaluate the objective response rate (ORR) of AMG 193 in adult participants with metastatic or locally advanced MTAP-null solid tumors


Alberta
Cross Cancer Institute, Edmonton

Ontario
Princess Margaret Cancer Centre, Toronto

Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer 

        ClinicalTrials.gov Identifier:        

         NCT03991819    

 

This study is currently recruiting participants.

This is a Phase I/Ib study whose purpose is to find out if combining an experimental drug called binimetinib with pembrolizumab is beneficial in people who have advanced non-small cell lung cancer. This study may also see if the combination is safe and may also find the best dose of binimetinib that should be added to pembrolizumab.
 
Ontario
Princess Margaret Cancer Centre, Toronto

 

 

 

Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer (ATLAS) 

        ClinicalTrials.gov Identifier:        

         NCT04966676   

 

This study is currently recruiting participants.
 

The purpose of this research study is to look at how effective two drugs, nivolumab and ipilimumab, are for people with non-small lung cancer that has metastasized (has spread to other parts of the body) and to see what effects these drugs have on these tumors.

Ontario
Princess Margaret Cancer Centre, Toronto
 

An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) 

        ClinicalTrials.gov Identifier:        

         NCT04563338    

 

This study is currently recruiting participants.
 

This study is being done to look at how effective the drug, atezolizumab, with or without the drug bevacizumab, is for people with inoperable liver cancer or non-small lung cancer that has spread to the liver. This will be done by looking at the duration of time from starting the study drug(s) until the cancer worsens in study participants.
This study will collect blood and tumor tissue samples from participants to look at changes to their tumor(s) before and after receiving atezolizumab and/or bevacizumab.


Ontario
Princess Margaret Cancer Centre, Toronto

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors 

      ClinicalTrials.gov Identifier:      

       NCT03645928      

 

This study is currently recruiting participants.
 

A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with checkpoint inhibitors or TIL LN-144 (Lifileucel)/LN-145/LN-145-S1 as a single agent therapy.

Ontario
Toronto
 

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

        ClinicalTrials.gov Identifier:        

         NCT03793179    

 

This study is active, but not recruiting participants.

This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving first-line pembrolizumab followed by pemetrexed and carboplatin with or without pembrolizumab works better in treating patients with non-squamous non-small cell cancer.

 

Alberta
Calgary
Edmonton

British Colombia
Surrey
Vancouver

New Brunswick
Saint John

Ontario
Kingston 
St. Catherines
Thunder Bay
Toronto

Prince Edward Island
Charlottetown

Quebec
Montreal
Quebec City

Study of Pembrolizumab with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib in Stage III NSCLC (MK-7339-012/KEYLYNK-012)

 

        ClinicalTrials.gov Identifier:        

         NCT04380636       

 

This study is active, but not recruiting participants.

 

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced NSCLC.
 

Quebec
Centre Hopitalier de l'Universite de Montreal - CHUM, Montreal
 

       ClinicalTrials.gov Identifier:       

      NCT04619797      

 

This study is active, but not recruiting participants. 

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with pembrolizumab plus pemetrexed and carboplatin/cisplatin (Arm B) in participants with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC).

Alberta
Cross Cancer Institute, Edmonton
 
Ontario
Royal Victoria Regional Health Centre, Barrie
Victoria Hospital - London Health Sciences Centre, London
Lakeridge Health, Oshawa
Sault Area Hospital, Sault Ste Marie
Princess Margaret Cancer Centre, Toronto
 
Quebec
Universite de Montreal - Hopital Maisonneuve-Rosemount, Montreal
 

ClinicalTrials.gov Identifier:

NCT03564691

 

This study is active but not recruiting participants.

This study consists of several parts: dose escalation, dose expansion, dose expansion in Chinese participants residing in China, and coformulation. Dose escalation is to evaluate the safety, tolerability, and preliminary efficacy of MK-4830 monotherapy administration (Arms A and B) and in combination with pembrolizumab (Arm C). Dose expansion is to evaluate the objective response rate (ORR) of MK-4830 in combination with pembrolizumab (Arms A-F); evaluate the safety and tolerability of MK-4830 administered in combination with pembrolizumab, carboplatin, and pemetrexed (Arm G) and of MK-4830 administered in combination with pembrolizumab and lenvatinib (Arm H); evaluate the safety, tolerability and ORR of MK-4830 in combination with pembrolizumab plus chemotherapy (Arms I-L); and evaluate the safety and tolerability of MK-4830 in combination with pembrolizumab in Chinese participants from China (Arm M). The coformulation part (Arm N) evaluates the safety and tolerability of MK-4830A (coformulation of MK-4830 800 mg + pembrolizumab 200 mg). There is no formal hypothesis testing in this study.


Ontario

Hamilton
Ottawa
Toronto

 

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrilizumab (MK-3475) with or without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults with Metastatic Nonsquamous NSCLC (MK-7902-006/E7080-G000-315/LEAP-006)

         ClinicalTrials.gov Identifier:          

         NCT03829319          

 

This study is active but not recruiting participants

 

The purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults with metastatic nonsquamous non-small cell lung cancer.

Ontario
Juravinski Cancer Centre (Site 0407), Hamilton
Kingston Health Sciences Centre (Site 0414), Kingston
Lakeridge Health (Site 0406), Oshawa
Sault Area Hospital (Site 0413), Sault Ste Marie

Quebec
Hopital Cite de la Sante de Laval (Site 0400), Laval
CIUSSS l'Ouest de l'Ile de Montreal - St-Marys Hospital (Site 0412), Montreal
CIUSSS de la Mauricie et du Centre du Quebec (Site 0408), Trois-Rivieres  
CHU de Quebec - Universite Laval - Hotel Dieu de Quebec (Site 0403), Quebec  

  A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

         ClinicalTrials.gov Identifier:          

         NCT03516981        


This study is active but not currently recruiting paricipants. 

 

This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile [GEP] and tumor mutational burden [TMB]) will be randomized to receive pembrolizumab in combination with MK-1308, MK-4280, or lenvatinib. The primary hypotheses are as follows: In participants receiving pembrolizumab in combination with either MK-1308, MK-4280, or lenvatinib, the Objective Response Rate (ORR) will be 1) greater than 5% among participants with low GEP and low TMB, 2) greater than 20% among participants with low GEP and high TMB, 3) greater than 20% among participants with high GEP and low TMB, and 4) greater than 45% among participants with high GEP and high TMB.
 
Ontario
Sunnybrook Health Science Centre (Site 0304)              
Toronto, Ontario, Canada, M4N 3M5
Contact: Study Coordinator, 416-480-5000 x 7955      

 
Quebec
Jewish General Hospital (Site 0307)              
Montreal, Quebec, Canada, H3T 1E2
Contact: Study Coordinator, 514-340-8222 x 23674   
 

 

   Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)

 

         ClinicalTrials.gov Identifier:        

        NCT03631199       


This study is active but not curently recruiting. 

This is a phase III study of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC subjects.

The study will assess primarily the safety and tolerability (safety run-in part) of pembrolizumab plus platinum-based doublet chemotherapy with canakinumab and then the efficacy (double-blind, randomized, placebo controlled part) of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab.

Ontario 
Novartis Investigative Site                                 
Toronto, Ontario, Canada, M5G 1Z6
Novartis Investigative Site
Toronto, Ontario, Canada, M5G 1Z6

Alberta
Novartis Investigative Site
Edmonton, Alberta, Canada, T6G 1Z2

 

A Study of Novel Anti-cancer Agents in Patients with Previously Untreated NSCLC (MAGELLAN)

 

        ClinicalTrials.gov Identifier:        

         NCT03819465     

 

This study is active but not curently recruiting.

This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)

Alberta
Edmonton

Ontario
Ottawa
Toronto

Study of Pembrolizumab (MKL-3475) with or without Maintenance Olaparib in Frist-line Metastatic Squamous NSCLC (MK-7339-008/KEYLINK-008)

 

        ClinicalTrials.gov Identifier:        

         NCT03976362      

 

This study is active but not currently recruiting.

The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC.
 

Nova Scotia
Nova Scotia Health Authority (Site 0103), Halifax

Ontario
Juravinski Cancer Centre (Site 0107), Hamilton
Kingston Health Sciences Centre (Site 0102), Kingston
Stronach Regional Cancer Centre (Site 0100), Newmarket

Quebec
CISSS de la Monteregie-Centre (Site 0101), Greenfield Park
Hopital Cite de la Sante de Laval (Site 0105), Laval
CIUSSS Ouest de l'Ile - St Mary's Hospital, Montreal
CIUSSS de la Mauricie et du Centre du Quebec (Site 0106), Trois-Rivieres 

 

An Open-Label, Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)

        ClinicalTrials.gov Identifier:        

         NCT02477826       

 

This study is active but not curently recruiting. 

 

An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC).
The purpose of this study is to show that nivolumab, or nivolumab plus ipilimumab, or nivolumab plus platinum-doublet chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in subjects advanced lung cancer.

Alberta
Cross Cancer Institute, Edmonton

Newfoundland and Labrador
St. John’s NL

Ontario
London

Quebec
Montreal
Rimouski
Trois Rivieres

Saskatchewan
Regina
Saskatoon

Trial of BMS-986012 in Combination With Platinum and Etoposide

        ClinicalTrials.gov Identifier:        

         NCT02815592      

 

This study is active but not curently recruiting

The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.

Alberta
Local Institution
Edmonton, T6G 1Z2
Contact: Site 0005   
 
Ontario
Local Institution
Ottawa,  K1H 8L6
Contact: Site 0008   
     
Local Institution
Toronto,  M5G 2M9
Contact: Site 0006    

A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)

 

        ClinicalTrials.gov Identifier:        

         NCT04026412      

 


This study is active but not currently recruiting.
 

The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab (Arm A) vs CCRT followed by durvalumab (Arm C) in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

Ontario
Kingston
London
Oshawa
Windsor

Quebec
CISSS du Bas-Saint Laurent Hopital Regional de Rimouski
Troid-Rivieres

Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease (ASPIRE-ILD)

      ClinicalTrials.gov Identifier:      

      NCT03485378     


This study is active but not currently recruiting.
   

This is a prospective phase II study of Stereotactic Ablative Radiotherapy (SABR) in patients with Non-Small Cell Lung Cancer (NSCLC) and co-existent Interstitial Lung Disease (ILD), to determine oncologic and toxicity outcomes. Patients will be divided into 3 separate cohorts based on the ILD-GAP index.
 
Ontario
London Regional Cancer Program of the Lawson Health Research Institute
UHN Princess Margaret Cancer Centre
 
Quebec
CHUM Université de Montréal